Interesting biotech paradox: Celldex (CLDX) vs Jasper (JSPR) on systemic mast cell depletion.
Both companies are developing anti-KIT antibodies designed to produce near-complete mast cell depletion as a way to control mast cell-driven inflammatory diseases such as chronic spontaneous urticaria. The mechanism is powerful: suppress KIT, drive plasma tryptase very low, and achieve prolonged mast cell reduction. But the biology may be a double-edged sword. Mast cells appear to have protective roles in host defense, and KIT signaling also matters upstream in hematopoiesis, raising a real question about how much immune risk comes with long-lasting depletion. In the clinical data discussed so far, adverse events such as neutropenia are especially worth watching.
What I find fascinating is the valuation gap. Based on the data I reviewed, CLDX is valued dramatically above JSPR, even though both are pursuing broadly similar mast cell-ablation logic. CLDX is further ahead, with Phase 3 CSU studies and a much larger cash position, while Jasper is still earlier-stage with briquilimab in active studies for CSU/CIndU/asthma. That explains part of the spread. But if CLDX Phase 3 succeeds cleanly, doesn’t that meaningfully de-risk the broader anti-KIT / mast cell depletion thesis for Jasper too?
So here’s the question for the forum:
Is the market correctly pricing platform maturity and financing risk, or is JSPR massively undervalued as a read-through trade on CLDX?
Q4 2026 could become a real judgment point for this whole therapeutic concept: either validation of systemic mast cell depletion as a major inflammatory disease strategy, or a reminder that eliminating an entire immune cell compartment may carry liabilities the market has underestimated.
Curious how others here think about:
- biological risk vs platform promise
- CLDX as leader vs JSPR as asymmetric catch-up
- whether anti-KIT mast cell depletion is a durable category or a safety trap
Not investment advice, just a discussion.